Compare Amgen, Inc. (AMGN) vs Iris Energy Limited (IREN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Iris Energy Limited — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Iris Energy Limited trades at $40.54 (market cap $14.70B). The key difference: Amgen, Inc. is far larger — about 13.3× Iris Energy Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| AMGN | IREN | |
|---|---|---|
Market Cap | $196.12B | $14.70B |
Sector | Health | Energy |
52-Week High | $388.16 | $76.41 |
52-Week Low | $271.18 | $15.40 |
Enterprise Value | $241.41B | $16.45B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IREN trades at $41.11, down 1.46% on the day, amid a bearish technical signal with key support at $40. The company is transitioning from Bitcoin mining to AI infrastructure, with revenue growing from $501M in 2025 to a projected $757M in 2026. Recent earnings have missed expectations, but analyst sentiment remains largely positive with a consensus price target of $79.11, representing significant upside potential from current levels.
The outlook hinges on successful execution of its AI cloud strategy, with a $3.1B contracted ARR target by end-2026 being a key catalyst. However, risks include intense competition, high capital expenditure evidenced by negative investing cash flow, and recent earnings misses. The stock offers high growth potential but carries substantial execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
